Hetero’s Tocilizumab biosimilar gets emergency use authorisation from DCGI for COVID treatment
This authorisation will enable medical practitioners to use the drug for the treatment of COVID-19 in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen. (Representational image: IE)
Drug firm Hetero on Monday said it has received emergency use authorisation from Drug Controller General of India (DCGI) for its biosimilar version of Tocilizumab for treatment of COVID-19 in hospitalised adults. The company will market the drug under the brand name ‘Tocira’, Hetero said in a statement.
This authorisation will enable medical practitioners to use the drug for the treatment of COVID-19 in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation, it added.
“This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the government to ensure equitable distribution,” Hetero Group Chairman, B Partha Saradhi Reddy said. Tocira will be marketed by Hetero’s associate company Hetero Healthcare in India.
Hetero’s biologics arm, Hetero Biopharma will manufacture the drug at its dedicated biologics facility, based at Jadcherla in Hyderabad, the statement said. The company’s Tocilizumab 400mg/20ml is the biosimilar version of Roche’s Actemra/RoActemra, and will be available from September-end, it added.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
